Lake Point Wealth Management acquired a new stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,210 shares of the biopharmaceutical company’s stock, valued at approximately $274,000.
Other institutional investors also recently modified their holdings of the company. Capital Financial Planning LLC purchased a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $28,000. Well Done LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth $30,000. Riverview Trust Co purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth $33,000. Portfolio Solutions LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth $37,000. Finally, Gantzert Investment Co. LLC ADV purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth $39,000. Institutional investors own 74.28% of the company’s stock.
BMY opened at $46.50 on Tuesday. The firm has a market cap of $74.40 billion, a P/E ratio of 11.68, a P/E/G ratio of 2.34 and a beta of 0.80. Bristol-Myers Squibb Co has a fifty-two week low of $44.30 and a fifty-two week high of $63.69. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.61 and a quick ratio of 1.50.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.09. The company had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. Bristol-Myers Squibb’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the company posted $0.68 earnings per share. As a group, research analysts predict that Bristol-Myers Squibb Co will post 4.16 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a dividend of $0.41 per share. The ex-dividend date is Thursday, April 4th. This represents a $1.64 annualized dividend and a yield of 3.53%. Bristol-Myers Squibb’s payout ratio is 41.21%.
A number of analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Monday, April 8th. ValuEngine cut shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 4th. BMO Capital Markets increased their price objective on shares of Bristol-Myers Squibb to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 20th. Bank of America reduced their price objective on shares of Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a research note on Tuesday, February 19th. Finally, Credit Suisse Group reissued a “hold” rating and issued a $59.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, February 15th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $59.13.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
See Also: Real Estate Investment Trust (REIT) ETF
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.